HB373 enacts an Adult‑Use Cannabis Pilot Program that lets Louisiana's existing medical cannabis infrastructure sell adult‑use cannabis on a temporary, statewide pilot basis under rules set by the Louisiana Department of Health (LDH). The bill limits participation to licensees and retailers already authorized under the state's therapeutic marijuana law, mandates state tracking and lab testing under existing medical rules, and preserves key statutory caps and local zoning continuity.
The measure matters because it creates the state's first structured experiment with adult‑use cannabis without issuing a new class of licenses. That choice shortens startup friction for regulators and businesses but concentrates market access among incumbents, changes wholesale fee and tax flows, and sets a defined end date for policy evaluation and potential permanent adoption.
At a Glance
What It Does
The bill authorizes LDH to regulate cultivation, processing, testing, transport, and retail sale of adult‑use cannabis during a temporary pilot and requires participants to use the state's existing seed‑to‑sale tracking system. It creates a pilot permit program, a reporting regime aligned with medical marijuana rules, and suspends certain existing fee provisions for the pilot's duration.
Who It Affects
Directly affects medical cannabis permit holders, cultivators, processors, and testing laboratories already licensed under Louisiana's therapeutic marijuana law, plus LDH and the Department of Revenue. Local zoning officials and parish governments also are affected because the bill deems pilot participation a continuation of lawful use.
Why It Matters
The bill tests adult‑use retail in a controlled way by reusing established infrastructure instead of opening a broader licensing process, shifting near‑term revenue and regulatory obligations to existing operators and state agencies. Compliance officers, tax teams, and operators will need to adapt medical‑grade reporting and testing workflows to an expanded consumer base.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
HB373 adds a new statute titled the Adult‑Use Cannabis Pilot Program Regulation and Enforcement Act. It gives the Louisiana Department of Health authority to regulate adult‑use cannabis across the same operational domains LDH currently governs for therapeutic marijuana—cultivation, extraction, processing, production, transport, retail sale, and independent lab testing—and directs LDH to rely on the public health sanitary code and existing medical rules where appropriate.
The statute explicitly allows LDH to promulgate additional rules under the Administrative Procedure Act to implement pilot‑specific details.
Participation in the pilot is constrained to the organizations already licensed under the therapeutic marijuana framework. Retailers and licensees must notify LDH of intent to participate within a defined pre‑start window and designate the single retail location in their region that will serve adult consumers during the pilot.
Those who decline participation remain in the medical program but are barred from joining the pilot later. All participants must connect to and report through the Louisiana Medical Marijuana Tracking System (LMMTS) for seed‑to‑sale traceability, except for LMMTS functions tied only to clinical recommendations and patient records.Testing and laboratory work for adult‑use product must follow the same standards and testing rules LDH applies to therapeutic marijuana; laboratories must apply for authorization and maintain LMMTS connectivity.
LDH issues initial pilot permits on a set date and then on a regular annual schedule; permits are time‑limited and renewable for one‑year terms. The bill imposes an annual permit fee for participating retailers, cultivators, and labs, changes the wholesale fee structure for participating growers for the pilot's term, and specifies that revenues are collected by the Department of Revenue and transferred to a named state fund.
Sales and use taxes apply to retail transactions during the pilot, and the statute explicitly preserves existing statutory caps and license limits from the therapeutic program while deeming pilot uses lawful under local zoning codes. The pilot has a statutory termination date, after which the pilot authorities and fee changes end unless otherwise reenacted.
The Five Things You Need to Know
The pilot begins January 1, 2027, and terminates July 1, 2030.
LDH must receive participant notifications no later than 90 days before the pilot start, and each participating retail permit holder designates one retail location in-region to serve adult consumers.
The department assesses a $5,000 annual pilot permit renewal fee for each participating retail location, cultivator, and laboratory.
For the pilot's duration, licensed cultivators participating in the pilot pay a wholesale fee equal to 3.5% of gross wholesales of marijuana (therapeutic and adult‑use); cultivators that decline to participate continue to pay the existing 7% fee on therapeutic sales.
The statute preserves existing program caps from R.S. 40:1046 et seq.: no more than 30 total retail locations (with up to 10 authorized to sell both therapeutic and adult‑use) and no more than two cultivation licensees, and it deems pilot participation a lawful continuation under current local zoning classifications.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Act name and purpose
This opening subsection names the law and lays out the pilot's stated goals: to test operational practicality, identify deployment risks, collect real‑time data, and allow modification or abandonment before a permanent rollout. Practically, it frames the pilot as an experimental, time‑limited program focused on public health and regulatory learnings rather than immediate full legalization.
Definitions that limit product scope
Defines 'adult‑use cannabis' narrowly as plant‑derived material containing naturally occurring THC and explicitly excludes synthetically derived or chemically altered cannabinoids from hemp. It also defines LDH, the LMMTS, 'pilot program', and THC for use throughout the statute. These definitions constrain what products may be sold under the pilot and signal LDH's authority over product standards and classifications.
Regulatory architecture, LMMTS, and testing
Assigns LDH regulatory authority across the adult‑use supply chain and requires participants to follow existing medical sanitary and testing rules where applicable. It mandates end‑to‑end tracking through LMMTS for cultivators, retailers, and labs, and requires labs to submit applications and maintain connectivity. The practical implication: operators will adapt medical reporting and lab protocols for broader consumer distribution rather than building a parallel adult‑use system.
Participation rules, permits, and fees
Limits sales and production authority to entities already licensed under the therapeutic scheme and requires a pre‑start notification and site designation. LDH issues initial permits on a fixed date and then on an annual schedule; permits run one year and are renewable subject to fee payment. The statute sets an annual $5,000 renewal fee for each participating retail site, cultivator, and lab and replaces the usual wholesale fee schedule for pilot participants with a different rate collected by the Department of Revenue and transferred to a designated state fund.
Taxes, statutory limits, zoning, and sunset
Clarifies that state and local sales and use taxes apply to retail adult‑use transactions during the pilot and that revenues from the new wholesale fee are routed to the Disability Services Fund. It preserves existing statutory caps on retail locations and cultivators from the therapeutic law and declares that pilot participation is a permitted continuation of existing lawful uses under local zoning codes. The pilot’s termination date is statutory, creating an automatic end point for the program and fee changes.
Sales tax exemption clarified
Amends the medical marijuana sales tax exemption to confirm that the exemption continues to apply only to therapeutic marijuana; it explicitly excludes any other retail sale or sale at retail of marijuana (i.e., adult‑use sales during the pilot are not exempt). This preserves the state's ability to collect sales tax on pilot transactions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Existing medical retailers that participate — gain access to a new adult‑use consumer market at their designated retail site without applying for new license classes, creating an immediate additional revenue stream.
- Cultivators and processors that opt into the pilot — obtain access to adult‑use demand channels while paying a lower pilot wholesale fee, potentially improving margins and justifying expanded production.
- Testing laboratories that participate — receive new business from adult‑use product testing and benefit from an established medical testing standard and LMMTS integration that lowers regulatory uncertainty.
- State programs funded by fees — the Department of Revenue’s transfers to the Disability Services Fund provide a new revenue stream earmarked for an existing state purpose during the pilot.
- Local zoning administrators and permitting offices — avoid contentious rezoning decisions because pilot participation is treated as a continuation of lawful use, reducing local litigation and administrative work tied to land‑use changes.
Who Bears the Cost
- Licensed operators who decline to participate — forgo adult‑use market access for the pilot period and continue paying existing fees on therapeutic sales while competitors gain a new revenue channel.
- Department of Health — takes on expanded regulatory design, inspection, tracking, and enforcement duties with limited statutory implementation detail and potential workload spikes at permit issuance and during audits.
- Department of Revenue — must collect a new wholesale fee and transfer revenues monthly to a designated fund, increasing administrative tasks and reconciliation responsibilities tied to LMMTS reporting.
- Consumers — adult purchasers will pay state and local sales and use taxes on retail purchases during the pilot and face a constrained retail footprint because pilot participation is limited by existing location caps.
- Testing labs and operators — must invest in LMMTS connectivity, adapt medical testing protocols to higher throughput, and pay the pilot permit fee; compliance costs could be significant up front.
Key Issues
The Core Tension
The central dilemma is whether to test adult‑use sales quickly by leveraging medical licensees—which minimizes startup friction and regulatory complexity but limits market access and locks in incumbents—or to delay for a broader licensing approach that would promote competition and wider access but require more time, new administrative capacity, and potentially greater local control.
The bill deliberately repurposes Louisiana’s medical cannabis framework to launch adult‑use sales rather than create a separate licensing regime. That approach reduces initial setup time and leverages existing traceability and testing infrastructure, but it also concentrates market access among incumbents and preserves statutory location and cultivator caps.
Because retailers must designate a single participating site and entities that decline are barred from later entry during the pilot, the statute creates a closed cohort for the pilot period, which could shape market structure and competitive dynamics in ways that persist after the pilot ends.
Operationally, the statute leans heavily on the LMMTS and medical testing rules without spelling out adaptations needed for large‑volume retail consumer sales (for example, retail inventory segregation, packaging and labeling for adult consumers, and privacy protections for consumer data). The reduced wholesale fee for participants versus the standing 7% fee raises questions about fairness and incentives: it encourages participation but may skew revenue allocations and competitive parity between participants and nonparticipants.
Finally, the zoning continuation clause removes a common local check on retail siting, reducing municipal discretion and potentially prompting political pushback despite the statutory preemption.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.